Semax Peptide Suppresses Brain Inflammation After Ischemic Stroke in Rats
Background
Ischemic stroke, caused by a lack of blood flow to the brain, triggers a severe inflammatory response that significantly contributes to neuronal damage and poor outcomes. This post-stroke inflammation involves the upregulation of various proinflammatory mediators, which can exacerbate brain injury. Understanding how to modulate this inflammatory cascade is crucial for developing effective neuroprotective strategies. This study specifically investigated the ability of the peptide drug ACTH(4-7)PGP (Semax) to suppress the mRNA transcripts encoding these proinflammatory mediators following reversible brain ischemia.
Results
The study found that ACTH(4-7)PGP (Semax) significantly attenuated the ischemia-induced increase in several key proinflammatory mRNA transcripts. Specifically, TNF-alpha mRNA levels were reduced by 43% (p<0.01) in the Semax-treated group compared to ischemic controls. Similarly, IL-6 mRNA expression showed a 38% decrease (p<0.05), and iNOS (inducible nitric oxide synthase) mRNA was suppressed by 32% (p<0.05). The peptide also demonstrated a notable reduction in COX-2 (cyclooxygenase-2) mRNA, decreasing its expression by 27% (p<0.05). > This comprehensive suppression of multiple proinflammatory gene transcripts highlights Semax's potent anti-inflammatory action at the molecular level following brain ischemia, offering a significant neuroprotective effect.
Why It Matters
This research provides strong molecular evidence for Semax's neuroprotective properties, specifically its ability to mitigate the detrimental inflammatory response after ischemic stroke. By suppressing the mRNA expression of key inflammatory mediators, Semax could potentially reduce secondary brain damage and improve neurological outcomes. This finding is particularly significant because Semax is already used clinically in some regions, suggesting a faster path to potential clinical translation as an adjunctive therapy for acute ischemic stroke. Future research should focus on validating these findings at the protein level and in larger animal models, paving the way for Phase II human trials in stroke patients.